IN2014DN03464A - - Google Patents

Download PDF

Info

Publication number
IN2014DN03464A
IN2014DN03464A IN3464DEN2014A IN2014DN03464A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A IN 3464DEN2014 A IN3464DEN2014 A IN 3464DEN2014A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A
Authority
IN
India
Prior art keywords
providing neuroprotection
stroke
mirna
administering
variant
Prior art date
Application number
Inventor
Suh hang H JUO
Yung Song Wang
Hsin Yun Cheng
Original Assignee
Dcb Usa Llc
Univ Kaohsiung Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcb Usa Llc, Univ Kaohsiung Medical filed Critical Dcb Usa Llc
Publication of IN2014DN03464A publication Critical patent/IN2014DN03464A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Abstract

The invention relates to a method for providing neuroprotection comprising administering to a subject an effective amount of a miRNA or a variant thereof. By providing neuroprotection stroke or ischemic stroke can be prevented and/or treated.
IN3464DEN2014 2011-11-03 2012-11-05 IN2014DN03464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555152P 2011-11-03 2011-11-03
PCT/US2012/063604 WO2013067531A2 (en) 2011-11-03 2012-11-05 Methods of using microrna 195 in providing neuroprotection

Publications (1)

Publication Number Publication Date
IN2014DN03464A true IN2014DN03464A (en) 2015-06-05

Family

ID=48193054

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3464DEN2014 IN2014DN03464A (en) 2011-11-03 2012-11-05

Country Status (7)

Country Link
US (1) US9315812B2 (en)
EP (1) EP2773381B1 (en)
JP (1) JP5888572B2 (en)
CN (1) CN104080910A (en)
IN (1) IN2014DN03464A (en)
TW (1) TWI462741B (en)
WO (1) WO2013067531A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916989A1 (en) * 2013-06-28 2014-12-31 London Health Sciences Centre Research Inc. Inhibition of microrna for treatment of sepsis
CN106474549B (en) 2016-11-21 2019-05-03 南通大学 The novel tissue tissue-engineered nerve of MicroRNA gene mediated constructs and its in the application for repairing neurologic defect
WO2018111784A1 (en) * 2016-12-14 2018-06-21 China Medical University Micro-rna-195 compositions and therapeutic use in ocular diseases
EP4100021A4 (en) * 2020-02-03 2023-11-15 Rutgers, the State University of New Jersey Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof
WO2022033529A1 (en) * 2020-08-12 2022-02-17 洪明奇 Use of sema3d antagonist in preventing or treating neurodegenerative diseases and prolonging lifespan
CN113599540B (en) * 2021-05-27 2023-05-23 山西医科大学 Application of miRNA-195-5p in preparation of reagent for inhibiting or reducing nerve cell damage caused by aluminum maltol
CN113308535A (en) * 2021-06-11 2021-08-27 中国人民解放军空军军医大学 PD diagnosis and staging kit based on serum exosome miRNA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005078139A2 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
EP2111408A4 (en) * 2007-01-17 2010-02-03 Univ Johns Hopkins Compositions and methods featuring micronas for treating neoplasia
AU2008323652B2 (en) * 2007-11-09 2014-02-20 Board Of Regents, The University Of Texas System Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
EP2112235A1 (en) * 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
EP2239675A1 (en) * 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease
US8486909B2 (en) 2009-06-24 2013-07-16 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug

Also Published As

Publication number Publication date
WO2013067531A2 (en) 2013-05-10
JP5888572B2 (en) 2016-03-22
US20140294943A1 (en) 2014-10-02
EP2773381A4 (en) 2015-07-08
WO2013067531A3 (en) 2014-07-03
EP2773381B1 (en) 2020-06-03
TWI462741B (en) 2014-12-01
CN104080910A (en) 2014-10-01
EP2773381A2 (en) 2014-09-10
JP2014533248A (en) 2014-12-11
TW201322987A (en) 2013-06-16
US9315812B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
MX2019011905A (en) New compositions for treating amyotrophic lateral sclerosis.
EP2757887A4 (en) Pyrrolopyridinone compounds and methods for treating hiv
EP2736528A4 (en) Compositions and methods for the treatment of hiv
EP2938616A4 (en) The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
IN2014DN03464A (en)
MX368649B (en) Fungicidal penflufen mixtures.
MX364495B (en) Composition and method for treating nucleic acid-related eye disease.
IN2012MU03723A (en)
PL2763527T3 (en) Method for the fungicidal treatment of resistant strains using one or more essential oils
ZA201306990B (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
ZA201404327B (en) Composition comprising block cocondensates of propylfunctional alkaline siliconates and silicates, and method for the production thereof
PL2997173T3 (en) Method of production of zinc-coated steel for press hardening application
EP2758780A4 (en) Method for the treatment of multiple sclerosis
EP2739332A4 (en) Stopper/plunger for carpules of syringe-carpule assembly
IL229706A0 (en) Method of treating the effects of stroke
MX2015003034A (en) Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, method for the production thereof and use of same.
EP2683404A4 (en) The method of treating amyotrophic lateral sclerosis
HUE038149T2 (en) Method for the treatment of steels
HRP20180417T1 (en) Composition for treating hypoactive sexual desire disorder
HK1209052A1 (en) Method of treating scedosporium spp. infection
HRP20150141T1 (en) Use of nifuratel to treat infections caused by clostridium species
IN2013CH05865A (en)
UA65592U (en) method for treatment of associative backteriosEs of animals
UA106373C2 (en) Use of pollentarum as an agent with frigoprotective action